Document is current
Any future updates will be listed below
-
Authors
Oldenburg, Johannes https://orcid.org/0000-0002-1585-4100
Olivieri, Martin https://orcid.org/0000-0001-6434-6244
Yan, Songkai https://orcid.org/0000-0002-1677-3839
Yang, Ying https://orcid.org/0000-0001-7079-5927
Tomic, Radovan
Zhang, Xiang
Drelich, Douglass https://orcid.org/0009-0004-7388-2013
Jakobs, Natalie
Napolitano, Mariasanta https://orcid.org/0000-0001-8934-2936
-
Funding
Funding for this research was provided by:
CSL Behring
- License Information
-
More Information
Article History
Received: 23 April 2025
Accepted: 30 June 2025
First Online: 23 July 2025
Declarations
:
: Johannes Oldenburg has received research funding from Bayer, Biotest, CSL Behring, Octapharma, Pfizer, Swedish Orphan Biovitrum and Takeda; consultancy, speakers bureau, honoraria, scientific advisory board and travel expenses from Bayer, Biogen Idec, BioMarin, Biotest, Chugai, CSL Behring, Freeline, Grifols, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Spark Therapeutics, Swedish Orphan Biovitrum and Takeda; Martin Olivieri has received grants/research support from Bayer, Biomarin, Biotest, Takeda, CSL Behring Octapharma, Pfizer, Shire, Roche, Stago and Swedish Orphan Biovitrium, consultancy and speaker fees from Bayer, BioMarin, Biotest, Novo Nordisk, Takeda, CSL Behring, Pfizer, Roche and Swedish Orphan Biovitrium; Songkai Yan, Radovan Tomic, Xiang Zhang and Douglass Drelich are employees of CSL Behring; Ying Yang and Natalie Jakobs are employees of Adivo Associates; Mariasanta Napolitano has acted as consultant for Bayer, Novo Nordisk, Sobi, Kedrion, and has received speaker fees from Takeda, CSL Behring, Bayer, Novo Nordisk, Kedrion, Novartis, Amgen, Sobi, Sanofi Genzyme, Pfizer.
: Following IRB evaluation, the study was determined to be exempt from IRB oversight as it was secondary research using non-identifiable information for which informed consent is not required.
